Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis

Autor: J A Dijkstra, Jan-Willem C. Alffenaar, M E van der Meer, J F Borjas Howard, R. van Altena, D. van Soolingen, T S van der Werf, Jos G. W. Kosterink

Publikováno v: Antimicrobial Agents and Chemotherapy, 61, e01400-16-e01400-16
Antimicrobial Agents and Chemotherapy, 61(3). American Society for Microbiology
Antimicrobial Agents and Chemotherapy, 61(3):UNSP e01400-16. AMER SOC MICROBIOLOGY
van Altena, R, Dijkstra, J A, van der Meer, M E, Borjas Howard, J F, Kosterink, J G W, van Soolingen, D, van der Werf, T S & Alffenaar, J W C 2017, ' Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis ', Antimicrobial Agents and Chemotherapy, vol. 61, no. 3 . https://doi.org/10.1128/AAC.01400-16
Antimicrobial Agents and Chemotherapy, 61, 3, pp. e01400-16-e01400-16

Hearing loss and nephrotoxicity are associated with prolonged treatment duration and higher dosage of amikacin and kanamycin. In our tuberculosis center, we used therapeutic drug monitoring (TDM) targeting preset pharmacokinetic/pharmacodynamic (PK/P

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bdac79b0c4f8853428eac4d08e28050
http://hdl.handle.net/2066/170279